公开(公告)号：US11976083B2

公开(公告)日：2024-05-07

申请号：US17242617

申请日：2021-04-28

Applicant: Gilead Sciences, Inc.

Inventor： Eda Y. Canales ,  Weng K. Chang ,  Laurent P. Debien ,  Petr Jansa ,  Jennifer A. Loyer-Drew ,  Luisruben P. Martinez ,  Stephane Perreault ,  Gary B Phillips ,  Hyung-Jung Pyun ,  Roland D. Saito ,  Michael S. Sangi ,  Adam J. Schrier ,  Marina E. Shatskikh ,  James G. Taylor ,  Jennifer A. Treiberg ,  Joshua J. Van Veldhuizen

IPC: C07D471/18 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/437 ,  A61K45/06 ,  A61P3/10 ,  A61P7/02 ,  A61P19/02 ,  A61P35/00 ,  C07D471/12 ,  C07D471/14 ,  C07D487/08 ,  C07D491/22 ,  C07D498/18 ,  C07D498/22 ,  C07D513/18 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61K45/06 ,  C07D471/14

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.